RT Journal Article SR Electronic T1 T Cell Positive B Cell Negative Flow Cytometry Crossmatch (FCXM): Frequency, HLA-Locus Specificity, and Mechanisms Among 3073 Clinical FCXM Tests JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.05.20.21257541 DO 10.1101/2021.05.20.21257541 A1 Prabhakar Putheti A1 Vijay K Sharma A1 Rex Friedlander A1 Arvind Menon A1 Darshana Dadhania A1 Thangamani Muthukumar A1 Manikkam Suthanthiran YR 2021 UL http://medrxiv.org/content/early/2021/05/24/2021.05.20.21257541.abstract AB Background A T cell positive and B cell negative (T+B-) flow cytometry crossmatch (FCXM) result remains a conundrum since HLA-class I antigens are expressed on both T and B cells. We investigated the frequency, HLA specificity of the antibodies and mechanisms for the T+B- FCXM result.Methods We analyzed 3073 clinical FCXM tests performed in an American Society of Histocompatibility and Immunogenetics accredited histocompatibility laboratory. The sera associated with the T+B- FCXM were also tested for donor HLA IgG antibodies using LABScreen™ single antigen assays.Results Among the 3073 FCXM tests, 1963 were T-B-, 811 were T-B+, 274 were T+B+, and 25 were T+B-. IgG antibodies directed at donor HLA-A, B, or Cw locus determined antigens (DSA) were identified in all 25 sera and the summed mean fluorescence intensity (MFI) of DSA ranged from 212 to 53,187. Correlational analyses identified a significant association between the summed MFI of class I DSA, and the median channel fluorescence (MCF) of T cells treated with the recipient serum (Spearman rank correlation, rs=0.34, P=0.05) but not with the MCF of B cells (rs=0.23, P=0.24). We identified that differential binding of anti-HLA antibodies to T cells and B cells and the B cell channel shift threshold used to classify a B cell FCXM are potential contributors to a T+B- FCXM result.Conclusions Our analysis of 3073 FCXM, in addition to demonstrating that HLA antibodies directed at HLA-A, B or Cw locus are associated with a T+B- result, identified mechanisms for the surprising T+B- FCXM result.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Weill Cornell Medicine Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicableACDAcid Citrate DextroseB cellB lymphocyteCDcluster of differentiationCDC-XMcomplement dependent cytotoxicity crossmatchCSchannel shiftDSAdonor specific antibodyEDTAEthylenediaminetetraacetic acidF(ab’)2fragment antigen-bindingFcfragement crystallizableFCXMflow cytometry crossmatchFITCFluorescein isothiocyanateFSCforward scatterHLAhuman leukocyte antigenIgGImmunoglobulin GIQRinterquartile rangeLSALuminex single antigenmAbmonoclonal antbodyMCFmedian channel fluorescenceMFImean fluorescence intensityNCSnegative control serumPBMCperipheral blood mononuclear cellsPBSphosphate buffered salinePCSpositive control serumPEPhycoerythrinPerCPPeridinin-Chlorophyll-ProteinRSrecipient serumSSCside scatterT cellT lymphocyte